Redhill Biopharma (NASDAQ:RDHL) Share Price Crosses Below 200-Day Moving Average – What’s Next?

Redhill Biopharma Ltd. (NASDAQ:RDHL)’s stock price crossed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $1.27 and traded as low as $0.87. Redhill Biopharma shares last traded at $0.8899, with a volume of 7,208 shares traded.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Redhill Biopharma in a research report on Thursday, January 22nd. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Redhill Biopharma Stock Performance

The company has a 50-day moving average of $1.05 and a 200-day moving average of $1.27. The stock has a market capitalization of $4.55 million, a price-to-earnings ratio of 0.00 and a beta of 4.91.

Hedge Funds Weigh In On Redhill Biopharma

A hedge fund recently bought a new stake in Redhill Biopharma stock. Gagnon Securities LLC acquired a new stake in shares of Redhill Biopharma Ltd. (NASDAQ:RDHL) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 17,822 shares of the biotechnology company’s stock, valued at approximately $39,000. Gagnon Securities LLC owned 0.54% of Redhill Biopharma as of its most recent filing with the Securities & Exchange Commission. 7.20% of the stock is currently owned by institutional investors and hedge funds.

Redhill Biopharma Company Profile

RedHill Biopharma Ltd. is a specialty biopharmaceutical company focused on the development and commercialization of proprietary, orally-administered small molecules for the treatment of inflammatory, gastrointestinal and oncology indications. Founded in 2009 and headquartered in Tel Aviv, Israel, RedHill is publicly traded on the Nasdaq under the symbol RDHL. The company’s strategy centers on in-licensing late-stage clinical candidates and advancing them through regulatory review toward global commercialization.

RedHill’s lead marketed product, Talicia® (formerly RHB-105), is an FDA-approved, three-drug treatment for Helicobacter pylori infection, co-commercialized in the United States through a partnership with Bausch Health.